Compensatory lung growth in autologous lobar implant: experimental study in dogs

Transplantation Proceedings
A J M Cataneo, D C Cataneo

Abstract

The best way to study compensatory lung growth (CLG) is in a transplant without rejection. Since immunosuppressive drugs may influence CLG, it is better to not use them. Therefore we studied CLG in a reimplant of only one lobe after its removal. The objective was to compare lobar transplant CLG with CLG after lobectomy. Forty eight dogs were distributed in three groups: G1 = control, G2 = left cranial lobectomy, and G3 = left pneumonectomy with reimplantation of the caudal lobe. Five months after surgery the animals underwent lung scintigraphy and were sacrificed for morphometric study. There was no correlation between scintigraphy and lung mass or lung volume. There was both mass and residual volume CLG in the operated groups, both contralateral and ipsilateral to surgery. There was no compensation for total lung capacity or compliance in the remaining caudal lobe (G2) or the reimplanted caudal lobe (G3) at 5 months after surgery. There was more damage in the reimplanted lobe. As previous studies have shown that CLG starts with increased mass and residual volume and compliance is compensated later. This study seemed to document the beginning of CLG, with lung compliance being the limiting factor of CLG at 5 months. There was C...Continue Reading

References

Mar 1, 1967·Biulleten' eksperimental'noĭ biologii i meditsiny·L K RomanovaK K Antipova
Apr 1, 1969·The Journal of Thoracic and Cardiovascular Surgery·Z SerýM Obrucník
Jan 1, 1995·The Annals of Thoracic Surgery·S E LangenburgI L Kron
Jul 1, 1994·The Journal of Clinical Investigation·C C HsiaE R Weibel
Oct 30, 1999·The Annals of Thoracic Surgery·L F DuebenerH J Schäfers

❮ Previous
Next ❯

Citations

Apr 15, 2011·Archivos de bronconeumología·Carlos Simón AdiegoFederico González-Aragoneses

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.